Diversified Trust Co Raises Position in Pfizer Inc. (NYSE:PFE)

Diversified Trust Co increased its holdings in Pfizer Inc. (NYSE:PFE) by 9.8% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 115,159 shares of the biopharmaceutical company’s stock after buying an additional 10,258 shares during the period. Diversified Trust Co’s holdings in Pfizer were worth $3,196,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in PFE. Teza Capital Management LLC purchased a new stake in Pfizer during the third quarter valued at about $347,000. Hodges Capital Management Inc. purchased a new stake in Pfizer during the third quarter valued at about $203,000. Truist Financial Corp increased its holdings in shares of Pfizer by 1.9% in the third quarter. Truist Financial Corp now owns 3,994,764 shares of the biopharmaceutical company’s stock worth $132,506,000 after buying an additional 74,746 shares during the period. Advisors Asset Management Inc. increased its holdings in shares of Pfizer by 2.8% in the third quarter. Advisors Asset Management Inc. now owns 564,577 shares of the biopharmaceutical company’s stock worth $18,727,000 after buying an additional 15,507 shares during the period. Finally, Axxcess Wealth Management LLC increased its holdings in shares of Pfizer by 178.3% in the third quarter. Axxcess Wealth Management LLC now owns 181,425 shares of the biopharmaceutical company’s stock worth $6,018,000 after buying an additional 116,243 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Pfizer stock opened at $28.22 on Tuesday. The stock’s 50 day simple moving average is $27.90 and its two-hundred day simple moving average is $27.69. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05. The stock has a market cap of $159.91 billion, a price-to-earnings ratio of -470.25, a PEG ratio of 1.10 and a beta of 0.69. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $37.80.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.26. The business had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The business’s revenue was down 19.5% on a year-over-year basis. During the same period in the previous year, the firm posted $1.23 EPS. As a group, analysts expect that Pfizer Inc. will post 2.38 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be given a $0.42 dividend. The ex-dividend date of this dividend is Thursday, July 25th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.95%. Pfizer’s dividend payout ratio is currently -2,799.53%.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Morgan Stanley lifted their price objective on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday, May 2nd. BMO Capital Markets reiterated an “outperform” rating and issued a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Wednesday, June 26th. Nine investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus target price of $35.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.